Latest / The High Net Worth Podcast with Fexingo: Wealth Management, Tax Strategy, and Affluent Finance / Family Offices Betting On Biofoundries
Transcript
- Lucas: Most people think when family offices bet big on biology, they’re buying shares in a clinical-stage drug company or a generic biotech ETF. But if you look at the check sizes moving quietly between now and late last year, there’s a different trend emerging. They’re buying into the factories themselves. Specifically, the automated biofoundries that act as the central nervous system for synthetic biology. Luna: Right, so instead of betting on which molecule wins, they’re funding the machines that design them? That feels like a much more defensible moat than any single product pipeline. Lucas: Exactly. And it makes sense given the current macro environment. In October of twenty twenty-six, liquidity in public biotech has been thin, and valuations have corrected sharply from the peak. Family offices, who usually prefer stable cash flows or hard assets, are finding a rare window to acquire equity in the infrastructure layer of an industry that’s finally hitting commercial scale. It’s not about the hype anymore; it’s about the throughput. Luna: So what does a biofoundry actually do that makes it worth a direct partnership? Is it just renting space? Lucas: It’s far more integrated than simple lab rental. A modern biofoundry combines high-throughput robotics, genomic sequencing, and machine learning to design, build, and test genetic circuits at a speed humans physically cannot match. Think of it as the semiconductor fab for biology. If you’re a food company wanting to create a new protein, or a chemical company trying to replace petroleum-based plastics, you don’t want to build your own lab. You want access to this pipeline. The family office structures a deal where they provide patient capital in exchange for preferred access to that capacity and a cut of the resulting intellectual property. Luna: That sounds efficient, but biological systems are notoriously messy. How do you underwrite risk when living things mutate and fail? Lucas: You underwrite it by focusing on the platform reliability, not the individual experiment. The key players here, like Ginkgo Bioworks, have spent years standardizing their processes. They’ve turned biology into a software-like workflow. The failure rate per strain is still high, but the cost of failure has dropped dramatically because the robots can iterate thousands of designs a week. For a family office, the argument is that you’re buying exposure to the aggregate success of the platform, not gambling on one specific enzyme. Luna: But doesn’t that make them dependent on the platform’s management? What happens if the leadership team stumbles? Lucas: That’s the real friction point. We saw Ginkgo’s stock get hammered recently as they tried to pivot from pure service fees to deeper co-development deals. The market hates uncertainty, and biological scaling is inherently uncertain. But family offices don’t trade on NASDAQ. They can negotiate covenants that protect them. They can secure minimum volume commitments or veto rights over certain strategic decisions. It’s a bespoke relationship, not a passive investment. Luna: So it’s really about negotiating leverage in a sector that’s still figuring out its unit economics. Lucas: Precisely. And let’s talk about the specific angle I’ve been tracking: the shift toward vertical integration. A few years ago, family offices were content being silent limited partners in venture funds focused on biotech. Now, they’re forming dedicated subsidiaries to partner directly with biofoundries. Why? Because they see the downstream opportunity. If you control the production method for sustainable aviation fuel or biodegradable polymers, you aren’t just an investor; you’re a supplier to your other portfolio companies. Luna: That creates internal demand. So the biofoundry isn’t just chasing external customers; it has guaranteed work from the family’s own holdings. Lucas: Exactly. It’s a closed-loop ecosystem. Let’s say the family owns a logistics firm. They’re under regulatory pressure to decarbonize their fleet. Instead of buying carbon credits, they invest in a biofoundry partnership that engineers yeast to produce drop-in jet fuel. They lock in the supply chain, hedge against volatile oil prices, and capture the margin upside in R&D. It’s a triple-play of risk mitigation, supply security, and alpha generation. Luna: That is a incredibly sophisticated way to view alternative energy. It moves the conversation from ESG compliance to actual competitive advantage. Lucas: It does. And this brings us to the financial mechanics, which is where most listeners might lose interest, but it’s critical. These deals are structured with significant upfront capital requirements. Biofoundries are capital-intensive. The robotics alone cost tens of millions. Plus, you need highly specialized talent—geneticists who understand automation. So the entry ticket is usually in the fifty to one hundred million dollar range for a meaningful stake. That filters out everyone except the ultra-wealthy or large institutional coalitions. Luna: And with interest rates staying elevated through this quarter, borrowing money to fund that kind of R&D is expensive. That probably pushes families toward equity deals even more. Lucas: Correct. Debt markets are reluctant to lend against biological IP until it’s proven at scale. Equity becomes the only viable option for early-stage growth. This creates a disconnect between public and private valuations. Public biotech stocks are trading at steep discounts to book value due to fear of clinical failure. Private biofoundry stakes, however, are priced based on future throughput potential. Smart money is exploiting that spread. Luna: So they’re buying the factory while the public is panicking about the product failures. It’s a classic contrarian play, but grounded in physical assets. Lucas: Yes, and it’s worth noting that these assets don’t become obsolete in five years like some software startups might. A biofoundry is a physical infrastructure asset. Once it’s built and calibrated, it has a long useful life. That appeals to the preservation mindset of family offices. They aren’t looking for a ten-bagger exit in two years; they’re looking for a durable income stream over fifteen to twenty years. Luna: Does that longevity mean they’re less likely to sell quickly? Or are they still expecting a major liquidity event down the road? Lucas: Both. They hold for the cash flow, yes, but they also position for an acquisition or IPO. When the sector consolidates—and it will, because no single company can dominate every vertical—the remaining platforms will be bought by giants like DowDuPont or Novartis. Those exits can be massive. But the family office doesn’t need to wait for that. They can monetize the technology through licensing fees in the interim. Luna: Licensing fees sound safer than relying on a successful exit. It provides steady revenue regardless of the market mood. Lucas: It does. And that’s the core thesis: treating biology as a utility. Just as you wouldn’t bet on a single car manufacturer when you own the steel mill, you shouldn’t bet on a single drug when you own the lab that designs the molecules. It’s a structural bet on the method, not the outcome. Luna: I’m curious about the talent aspect though. These labs need world-class scientists. Are family offices worried about brain drain or poaching? Lucas: They should be. Talent is the bottleneck. But many of these biofoundries have already solved the culture problem by offering equity to their researchers. It’s become a magnet for top-tier academic talent who want to see their work scaled industrially. The families are aware of this, which is why they often include governance provisions to ensure the scientific leadership remains autonomous. If you micromanage the science, you kill the innovation. Luna: So it’s a delicate balance of capital support without operational interference. Sounds like a lot of trust. Lucas: It is. Which leads me to a quick note on how we keep this show running. If our conversations about complex wealth strategies have helped you think about a decision differently, honestly, if today was worth a coffee to you, that’s the link — buy me a coffee dot com slash fexingo. It’s the smallest way to help keep these deep dives ad-free and available. Luna: Yeah, we appreciate it. It lets us spend more time digging into these niche sectors rather than chasing clicks. Lucas: Back to the biofoundry model. There’s a second layer to this that’s often overlooked: data. Every experiment run in a biofoundry generates data. Over time, that dataset becomes incredibly valuable for training AI models that predict protein folding or metabolic pathways. The family office isn’t just buying lab space; they’re acquiring a proprietary data asset that compounds in value. Luna: That’s the hidden gem. The wet lab builds the product, but the dry data builds the future edge. Who owns that data in these partnerships? Lucas: Usually, it’s shared, but the family office often gets first right of refusal on commercialization. It’s a smart negotiation point. In twenty twenty-four, we saw several deals where the data rights were explicitly carved out for the investor. It turns a traditional capex play into a data play. That’s very twenty twenty-six thinking. Luna: It really reframes the entire industry. It’s not just biology anymore; it’s biology plus big data. Lucas: Exactly. And let’s touch on the environmental angle briefly, since that’s a major driver. Investors are pushing hard for Scope Three emissions reductions. If a family office can use biofoundries to create sustainable materials for their manufacturing arm, they hit two birds with one stone: decarbonization and supply chain resilience. Luna: It’s practical sustainability. Not just buying offsets, but changing the input variables entirely. Lucas: Right. And that’s resilient. Even if regulations tighten further, they’re ahead of the curve. Their competitors are still stuck trying to comply with old standards. These families are setting new ones. Luna: Do you think this model will spread beyond family offices, or is it too complex for traditional corporate VC arms? Lucas: I think it’s starting to trickle up. Large corporates are tired of waiting for startup innovation. They’re setting up their own internal biofoundry units or partnering externally. But family offices move faster. They don’t have board committees approving each phase. They can deploy capital and sign term sheets in weeks, not months. That agility is their unfair advantage. Luna: Speed matters when you’re dealing with fast-moving technology. The window to establish dominance in a new sector is always narrow. Lucas: It is. And as the technology matures, those early movers will have entrenched relationships with the biggest players in pharma, agriculture, and materials. They’ll be the gatekeepers. Luna: Gatekeepers of the genome. That’s a powerful position to hold. Lucas: It is. But it requires patience. Most investors want quarterly results. Biofoundries operate on multi-year cycles. That mismatch is why this stays in the private realm for now. Luna: Unless the public markets correct enough to reward long-term conviction again. Lucas: Maybe. But for now, the action is off-chain. And that’s where the smartest money is hiding. Luna: Hiding in plain sight, building the future one cell at a time. Lucas: One cell at a time. It’s a reminder that in finance, as in biology, the smallest units often determine the survival of the whole. What do you think is the next vertical after materials and fuels? Luna: I’d bet on personal care. The demand for clean, lab-grown ingredients is exploding, and the margins are huge. Lucas: Personal care. High margin, low regulatory hurdle compared to drugs. You might be onto something there. We’ll keep an eye on it.